A Phase I Study to Assess a New Ebola Vaccine, cAd3-EBO Z
Research type
Research Study
Full title
A Phase Ia Dose-Escalating, Safety and Immunogenicity trial of the monovalent Zaire Ebola Chimpanzee Adenovirus vector candidate vaccine cAd3-EBO Z in healthy UK adults (EBL01)
IRAS ID
163198
Contact name
Heather House
Contact email
Sponsor organisation
Oxford University Hospitals NHS Foundation Trust
Eudract number
2014-003518-10
Research summary
This is a clinical trial in which healthy volunteers will be administered an experimental Ebola vaccine. We will vaccinate 3 groups of volunteers, at increasing doses with each group receiving a different dose of the vaccine.
The study will assess the safety of the vaccinations, and the immune responses to vaccination. Immune responses are measured by tests on blood samples.
The cAd3-EBO Z vaccine is a viral vectored vaccine. It is made from a virus which is modified so that it cannot multiply. The virus has extra DNA in it so that after injection, the body makes an Ebola protein (but Ebola does not develop), so that the immune system builds a response to Ebola without having been infected by it.
Healthy volunteers will be recruited in Oxford, England. The study will be funded by the Wellcome Trust.
REC name
South Central - Oxford A Research Ethics Committee
REC reference
14/SC/1256
Date of REC Opinion
9 Sep 2014
REC opinion
Further Information Favourable Opinion